PE20211475A1 - Inhibidores de kif18a - Google Patents
Inhibidores de kif18aInfo
- Publication number
- PE20211475A1 PE20211475A1 PE2021000930A PE2021000930A PE20211475A1 PE 20211475 A1 PE20211475 A1 PE 20211475A1 PE 2021000930 A PE2021000930 A PE 2021000930A PE 2021000930 A PE2021000930 A PE 2021000930A PE 20211475 A1 PE20211475 A1 PE 20211475A1
- Authority
- PE
- Peru
- Prior art keywords
- alk
- halo
- haloalk
- substituted
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Abstract
Compuestos de formula (I), donde: X1 es N o -CR6 ; R1 es -CN, o un grupo -Z-R12 en el que Z es -NR11 -, -NR11SO2-, entre otros; R2 es halo o un grupo -Y-R13, en el que Y es -alc C0-4-, -N(alc C0-1)-alc C0-4-, entre otros; R3 es H, alc C1-4, o haloalc C1-4; R4 es H, halo, R4a o R4b; R5 es H, halo, alc C1-8, o haloalc C1-4; R6 es H, halo, alc C1-8, haloalc C1-4, entre otros; R7 es H, halo, alc C1-8, o haloalc C1-4; R8 es H, halo, alc C1-8, haloalc C1-4, entre otros; R9 es H, halo, alc C1-8, o haloalc C1-4; Rx es a), b), c) o d); cada uno de R10a, R10b, R10c, R10d, R10e, R10f, R10g, R10h, R10i, y R10j es H, halo, R10k, o R10l; R11 es H, R11a, o R11b; R12 es H, R12a, o R12b; R13 es R13a o R13b; R4a, R10k, R11a, R12a, y R13a es un anillo monociclico de 3, 4, 5, 6 o 7 miembros saturado, parcialmente saturado o insaturado, entre otros; R4b, R8b, R10l, R11b, R12b, y R13b son alc C1-6 sustituido por 0, 1, 2, 3, 4, o 5 grupo(s) seleccionado(s) entre F, Cl, Br, -ORa , -Ohaloalc C1-4, o CN; Ra es H o Rb ; y Rb es alc C1-6, fenilo o bencilo, en el que el alc C1-6 esta siendo sustituido por 0, 1, 2 o 3 sustituyentes seleccionados entre halo, - OH, -alc OC1-4, -NH2, -NHalc C1-4, -OC(=O)alc C1-4, o -N(alc C1-4)alc C1-4; y el fenilo o bencilo esta siendo sustituido por 0, 1, 2 o 3 sustituyentes seleccionados entre halo, alc C1-4, haloalc C1-3, -OH, -Oalc C1-4, -NH2, entre otros. Dichos compuestos modulan la proteina KIF18A alterando de esta forma el proceso del ciclo celular y la proliferacion celular para tratar el cancer y enfermedades relacionadas con cancer. La invencion tambien incluye composiciones farmaceuticas, que incluyen los compuestos, y metodos para tratar patologias relacionadas con la actividad de KIF18A.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783061P | 2018-12-20 | 2018-12-20 | |
PCT/US2019/068169 WO2020132648A1 (en) | 2018-12-20 | 2019-12-20 | Kif18a inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211475A1 true PE20211475A1 (es) | 2021-08-05 |
Family
ID=69187977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000930A PE20211475A1 (es) | 2018-12-20 | 2019-12-20 | Inhibidores de kif18a |
Country Status (22)
Country | Link |
---|---|
US (2) | US11236069B2 (es) |
EP (1) | EP3897852A1 (es) |
JP (1) | JP7407196B2 (es) |
KR (1) | KR20210106474A (es) |
CN (1) | CN113226473A (es) |
AR (1) | AR117490A1 (es) |
AU (1) | AU2019403486A1 (es) |
BR (1) | BR112021011989A2 (es) |
CA (1) | CA3123871A1 (es) |
CL (1) | CL2021001634A1 (es) |
CO (1) | CO2021008224A2 (es) |
CR (1) | CR20210387A (es) |
EA (1) | EA202191730A1 (es) |
IL (1) | IL283639B1 (es) |
JO (1) | JOP20210154B1 (es) |
MA (1) | MA54543A (es) |
MX (1) | MX2021007156A (es) |
PE (1) | PE20211475A1 (es) |
SG (1) | SG11202106520VA (es) |
TW (1) | TW202034924A (es) |
UY (1) | UY38526A (es) |
WO (1) | WO2020132648A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3123871A1 (en) * | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
US20230151432A1 (en) * | 2020-04-14 | 2023-05-18 | Amgen Inc. | Kif18a inhibitors for treatment of neoplastic diseases |
CA3199082A1 (en) | 2020-10-27 | 2022-05-05 | Amgen Inc. | Heterocyclic spiro compounds and methods of use |
CA3217830A1 (en) | 2021-04-29 | 2022-11-03 | Amgen Inc. | 2-aminobenzothiazole compounds and methods of use thereof |
KR20240040742A (ko) | 2021-06-25 | 2024-03-28 | 항저우 인노게이트 파마 컴퍼니 리미티드 | Kif18a 억제제로서의 화합물 |
TW202321213A (zh) | 2021-07-21 | 2023-06-01 | 美商安進公司 | Kif18a抑制劑化合物之鹽和固態形式 |
WO2023028564A1 (en) * | 2021-08-26 | 2023-03-02 | Volastra Therapeutics, Inc. | Spiro indoline inhibitors of kif18a |
WO2023088441A1 (zh) * | 2021-11-19 | 2023-05-25 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
WO2023146973A1 (en) * | 2022-01-26 | 2023-08-03 | Amgen Inc. | Synthesis of a kif18a inhibitor |
WO2023159086A1 (en) | 2022-02-16 | 2023-08-24 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
WO2023159087A1 (en) | 2022-02-16 | 2023-08-24 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
WO2023174175A1 (zh) * | 2022-03-17 | 2023-09-21 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
TW202345802A (zh) * | 2022-04-15 | 2023-12-01 | 大陸商武漢人福創新藥物研發中心有限公司 | Kif18a抑制劑及其用途 |
WO2023217232A1 (zh) * | 2022-05-13 | 2023-11-16 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
WO2024002328A1 (zh) * | 2022-06-30 | 2024-01-04 | 勤浩医药(苏州)有限公司 | 一种含氮化合物及其应用 |
WO2024032661A1 (zh) * | 2022-08-11 | 2024-02-15 | 山东轩竹医药科技有限公司 | Kif18a抑制剂及其用途 |
WO2024035950A1 (en) * | 2022-08-12 | 2024-02-15 | Accent Therapeutics, Inc. | Inhibitors of kif18a and uses thereof |
WO2024039829A1 (en) * | 2022-08-18 | 2024-02-22 | Accent Therapeutics, Inc. | Inhibitors of kif18a and uses thereof |
WO2024051755A1 (zh) * | 2022-09-08 | 2024-03-14 | 长春金赛药业有限责任公司 | Kif18a抑制剂化合物、药物组合物及其制备方法和应用 |
WO2024051812A1 (zh) * | 2022-09-09 | 2024-03-14 | 先声再明医药有限公司 | 酰胺类化合物、其组合物及用途 |
WO2024067675A1 (zh) * | 2022-09-30 | 2024-04-04 | 长春金赛药业有限责任公司 | 稠环类kif18a抑制剂化合物、药物组合物及其制备方法和应用 |
WO2024067465A1 (zh) * | 2022-09-30 | 2024-04-04 | 山东轩竹医药科技有限公司 | Kif18a抑制剂 |
CN115594664B (zh) * | 2022-11-25 | 2023-02-24 | 英矽智能科技(上海)有限公司 | 一类螺环衍生物作为kif18a抑制剂 |
CN115947717B (zh) * | 2023-03-09 | 2023-05-30 | 英矽智能科技(上海)有限公司 | 一类kif18a抑制剂 |
Family Cites Families (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP2762522B2 (ja) | 1989-03-06 | 1998-06-04 | 藤沢薬品工業株式会社 | 血管新生阻害剤 |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
CA2148484A1 (en) | 1992-11-13 | 1994-05-26 | Stewart Lyman | Novel cytokine designated elk ligand |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
CA2148931A1 (en) | 1993-10-01 | 1995-04-13 | Jurg Zimmermann | Pyrimidineamine derivatives and processes for the preparation thereof |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
CN1046944C (zh) | 1993-12-17 | 1999-12-01 | 山道士有限公司 | 雷怕霉素类衍生物 |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
WO1995028484A1 (en) | 1994-04-15 | 1995-10-26 | Amgen Inc. | Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases |
ATE159257T1 (de) | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
JP4249804B2 (ja) | 1995-04-03 | 2009-04-08 | ノバルティス・アクチエンゲゼルシャフト | ピラゾール誘導体およびその製造法 |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
CA2219659C (en) | 1995-06-09 | 2008-03-18 | Novartis Ag | Rapamycin derivatives |
DE69619114T2 (de) | 1995-07-06 | 2002-10-02 | Novartis Ag | Pyrolopyrimidine und verfahren zu ihrer herstellung |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
EP0888349B1 (en) | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DK0888353T3 (da) | 1996-03-15 | 2003-10-27 | Novartis Ag | N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
ATE397660T1 (de) | 1996-08-16 | 2008-06-15 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
WO1998014450A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
WO1998014449A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
KR100372138B1 (ko) | 1997-08-08 | 2003-02-14 | 화이자 프로덕츠 인코포레이티드 | 아릴옥시아릴설포닐아미노 하이드록삼산 유도체 |
AU1102399A (en) | 1997-10-21 | 1999-05-10 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
CA2319236A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
EP1066286B1 (en) | 1998-03-04 | 2009-04-29 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
IL139934A (en) | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
JP2002520324A (ja) | 1998-07-10 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成インヒビター |
EP1109555A4 (en) | 1998-08-31 | 2001-11-21 | Merck & Co Inc | NEW ANGIOGENIC INHIBITORS |
PT1004578E (pt) | 1998-11-05 | 2004-06-30 | Pfizer Prod Inc | Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico |
IL144144A0 (en) | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
EP1165085B1 (en) | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
DK1187918T4 (da) | 1999-06-07 | 2009-02-23 | Immunex Corp | TEK-antagonister |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
DE60036945T2 (de) | 1999-07-12 | 2008-08-21 | Genentech, Inc., South San Francisco | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
EE05330B1 (et) | 1999-11-05 | 2010-08-16 | Astrazeneca Ab | Kinasoliini derivaadid kui VEGF-i inhibiitorid |
ATE514676T1 (de) | 1999-11-24 | 2011-07-15 | Sugen Inc | Ionisierbare indolinon derivate und deren verwendung als ptk liganden |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
NZ521437A (en) | 2000-02-25 | 2004-04-30 | Immunex Corp | Integrin antagonists suitable as inhibitors of angiogenesis |
US6651123B1 (en) | 2000-03-30 | 2003-11-18 | International Business Machines Corporation | File system locking |
US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
IL156306A0 (en) | 2000-12-21 | 2004-01-04 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US20050026868A1 (en) | 2003-07-11 | 2005-02-03 | Metcalf Chester A. | Phosphorus-containing macrocycles |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
RU2369636C2 (ru) | 2003-05-23 | 2009-10-10 | Уайт | Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения |
CA2531454C (en) | 2003-07-08 | 2011-10-25 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
AR045134A1 (es) | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
JP2007513962A (ja) | 2003-12-09 | 2007-05-31 | アメリカ合衆国 | 免疫応答を抑制するため、または増殖性障害を治療するための方法 |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
BRPI0510929A (pt) * | 2004-06-18 | 2007-07-17 | Chiron Corp | derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer |
DK1786785T3 (da) | 2004-08-26 | 2010-05-31 | Pfizer | Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere |
PE20060608A1 (es) | 2004-10-13 | 2006-08-22 | Wyeth Corp | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k |
PT1866339E (pt) | 2005-03-25 | 2013-09-03 | Gitr Inc | Moléculas de ligação a gitr e suas utilizações |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20090012085A1 (en) | 2005-09-20 | 2009-01-08 | Charles Michael Baum | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
US20070135435A1 (en) * | 2005-11-02 | 2007-06-14 | Xiangping Qian | Certain chemical entities, compositions, and methods |
US20110212086A1 (en) | 2006-01-19 | 2011-09-01 | Genzyme Corporation | GITR Antibodies For The Treatment of Cancer |
CL2007003520A1 (es) | 2006-12-07 | 2008-08-22 | Piramed Ltd Genentech Inc | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
KR101584823B1 (ko) | 2007-09-12 | 2016-01-22 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법 |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
WO2010030002A1 (ja) | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | 外来性gitrリガンド発現細胞 |
AR077033A1 (es) * | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
IN2015DN02826A (es) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
AU2010343056A1 (en) | 2009-12-29 | 2012-08-02 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
WO2011085261A1 (en) * | 2010-01-08 | 2011-07-14 | Selexagen Therapeutics, Inc. | Hedgehog inhibitors |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
PL3031799T3 (pl) * | 2013-08-09 | 2018-09-28 | Takeda Pharmaceutical Company Limited | Związek aromatyczny |
CA3123871A1 (en) * | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
MX2021007158A (es) * | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
EP3898592A1 (en) * | 2018-12-20 | 2021-10-27 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
WO2020132651A1 (en) * | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
-
2019
- 2019-12-20 CA CA3123871A patent/CA3123871A1/en active Pending
- 2019-12-20 CN CN201980083418.4A patent/CN113226473A/zh active Pending
- 2019-12-20 AR ARP190103828A patent/AR117490A1/es unknown
- 2019-12-20 JP JP2021534715A patent/JP7407196B2/ja active Active
- 2019-12-20 EA EA202191730A patent/EA202191730A1/ru unknown
- 2019-12-20 MX MX2021007156A patent/MX2021007156A/es unknown
- 2019-12-20 PE PE2021000930A patent/PE20211475A1/es unknown
- 2019-12-20 UY UY0001038526A patent/UY38526A/es unknown
- 2019-12-20 IL IL283639A patent/IL283639B1/en unknown
- 2019-12-20 WO PCT/US2019/068169 patent/WO2020132648A1/en unknown
- 2019-12-20 JO JOP/2021/0154A patent/JOP20210154B1/ar active
- 2019-12-20 CR CR20210387A patent/CR20210387A/es unknown
- 2019-12-20 AU AU2019403486A patent/AU2019403486A1/en active Pending
- 2019-12-20 BR BR112021011989-2A patent/BR112021011989A2/pt unknown
- 2019-12-20 EP EP19842520.9A patent/EP3897852A1/en active Pending
- 2019-12-20 SG SG11202106520VA patent/SG11202106520VA/en unknown
- 2019-12-20 KR KR1020217021507A patent/KR20210106474A/ko active Search and Examination
- 2019-12-20 TW TW108147097A patent/TW202034924A/zh unknown
- 2019-12-20 MA MA054543A patent/MA54543A/fr unknown
- 2019-12-20 US US16/724,119 patent/US11236069B2/en active Active
-
2021
- 2021-06-18 CL CL2021001634A patent/CL2021001634A1/es unknown
- 2021-06-23 CO CONC2021/0008224A patent/CO2021008224A2/es unknown
- 2021-12-14 US US17/551,105 patent/US20220106293A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220106293A1 (en) | 2022-04-07 |
TW202034924A (zh) | 2020-10-01 |
UY38526A (es) | 2020-06-30 |
CO2021008224A2 (es) | 2021-07-30 |
WO2020132648A1 (en) | 2020-06-25 |
CN113226473A (zh) | 2021-08-06 |
JP7407196B2 (ja) | 2023-12-28 |
EP3897852A1 (en) | 2021-10-27 |
CL2021001634A1 (es) | 2021-12-10 |
MX2021007156A (es) | 2021-08-16 |
MA54543A (fr) | 2022-03-30 |
US20200239441A1 (en) | 2020-07-30 |
IL283639B1 (en) | 2024-02-01 |
AU2019403486A1 (en) | 2021-06-24 |
SG11202106520VA (en) | 2021-07-29 |
KR20210106474A (ko) | 2021-08-30 |
BR112021011989A2 (pt) | 2021-09-08 |
AR117490A1 (es) | 2021-08-11 |
JOP20210154A1 (ar) | 2023-01-30 |
JOP20210154B1 (ar) | 2023-09-17 |
CR20210387A (es) | 2021-08-19 |
JP2022513972A (ja) | 2022-02-09 |
CA3123871A1 (en) | 2020-06-25 |
US11236069B2 (en) | 2022-02-01 |
EA202191730A1 (ru) | 2021-08-24 |
IL283639A (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211475A1 (es) | Inhibidores de kif18a | |
PE20221264A1 (es) | Inhibidores de egfr | |
PH12017500914A1 (en) | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | |
EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
PH12017500828A1 (en) | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | |
AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
EA201792214A1 (ru) | Соединения замещенного хиназолина | |
PE20180117A1 (es) | Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer | |
EA201691727A1 (ru) | Фосфонатные соединения для лечения опосредованных комплементом нарушений | |
PE20200342A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
PE20191479A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
PE20191478A1 (es) | Compuestos moduladores del receptor de hidorcarburos de arilo (ahr) | |
PE20170206A1 (es) | Inhibidores espirociclicos sustituidos de la autotaxina | |
EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
PH12021550388A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
PE20181319A1 (es) | Compuestos de isoindol | |
PE20190503A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
EA201691760A1 (ru) | Тритерпеноиды с активностью ингибиторов созревания вич, замещенные в положении 3 неароматическим кольцом, имеющим галогеналкильный заместитель | |
EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
PE20190979A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
PE20200340A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
PE20191535A1 (es) | Derivados de pirazol como inhibidores de bromodominio |